Arginine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Arginine: From Parenteral Nutrition Amino Acid Supply to Gastroparesis
One-Sentence Summary
Arginine is an amino acid used in Singapore as a component of intravenous nutrition and amino acid infusion products. The TxGNN model predicts it may be useful for gastroparesis, but there are currently no registered clinical trials and only 9 publications, almost all from animal studies, supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence data compiled for this report (products are parenteral nutrition and amino acid infusions) |
| Predicted New Indication | Gastroparesis |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, arginine is the substrate for nitric oxide synthase, which produces nitric oxide (NO). It is a standard component of amino acid infusions and parenteral nutrition, and mechanistically it may be applicable to gastroparesis.
The link to gastroparesis runs through NO signalling. Nitrergic nerves use NO to relax the stomach and pylorus, and this relaxation is needed for normal gastric accommodation and emptying. One mouse study found that glucocorticoids induced gastroparesis by depleting L-arginine, which suggests that arginine shortage may impair this pathway. A rat model of Parkinson's disease also showed impaired nitrergic relaxation in the pyloric sphincter.
This reasoning rests on animal data only. No human trial has tested arginine supplementation in gastroparesis, so the prediction remains a hypothesis. Several other retrieved papers concern gastric stimulation, diabetic neuropathy and ghrelin. They relate to gastroparesis but not to arginine.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25057793 | 2014 | Animal study | Endocrinology | Glucocorticoids induced gastroparesis in mice through depletion of L-arginine |
| 35380456 | 2022 | Animal study | Am J Physiol Gastrointest Liver Physiol | Impaired nitrergic relaxation in the pyloric sphincter of a Parkinson's disease rat model |
| 18312542 | 2008 | Animal study | Neurogastroenterol Motil | Myenteric neuropathy and nNOS expression in diabetic rats; reduced nNOS proposed as a mechanism of diabetic gastroparesis |
| 19023028 | 2009 | Animal study | Am J Physiol Gastrointest Liver Physiol | Gastric electrical stimulation improved gastric accommodation via the nitrergic pathway in dogs |
| 31984783 | 2020 | Animal study | Am J Physiol Gastrointest Liver Physiol | Sacral nerve stimulation increased gastric accommodation in rats |
| 21193530 | 2011 | Animal study | Am J Physiol Gastrointest Liver Physiol | Hyperglycaemia inhibited gastric motility through nodose ganglia KATP channels |
| 18322959 | 2008 | Animal study | World J Gastroenterol | Ghrelin and GHRP-6 effects on gastric motility in diabetic mice with gastroparesis |
| 8194696 | 1994 | Animal study | Gastroenterology | Gastric motor response to food protein-induced anaphylaxis in rats |
| 33867519 | 2021 | Case report | Am J Case Rep | Lifestyle changes normalised serum lactate in an m.3243A>G carrier (indirect relevance) |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16003P | LYSAKARE Solution for Infusion 25G/25G | Infusion, solution | Not stated |
| SIN16337P | AMINOVEN Solution for Infusion 15% | Infusion, solution | Not stated |
| SIN11682P | AMINOVEN Solution for Infusion 5% | Injection | Not stated |
| SIN11829P | AMINOVEN Solution for Infusion 10% | Injection | Not stated |
| SIN06299P | NEPHROSTERIL for Intravenous Infusion | Injection | Not stated |
A further 15 valid single-ingredient registrations exist, mainly parenteral nutrition emulsions and amino acid infusions (for example SmofKabiven, Nutriflex Omega, Oliclinomel, Aminoplasmal and Nutrineal PD4).
Safety Considerations
Please refer to the package insert for safety information.
Knowledge-graph data (not label text) link arginine to contraindication relationships with several conditions. These are not confirmed contraindications, and they should be checked against the product labels:
- Kidney and metabolic: chronic kidney disease, end stage renal failure, metabolic acidosis, renal tubular acidosis, nephrolithiasis, hypercalcemia, hyperparathyroidism, phenylketonuria
- Cardiovascular and other: heart disease, cardiovascular disease, ventricular fibrillation, digitalis poisoning, sickle cell anemia, sarcoidosis, constipation
No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high (99.42%), but the supporting evidence is limited to animal and mechanistic studies (L4). There are no clinical trials, and the key data on approved indications, mechanism of action and label safety are missing. The knowledge-graph contraindications, especially renal and cardiovascular, call for caution.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA, to allow safety screening
- Approved indication text for the Singapore products
- Mechanism of action data from DrugBank
- Human pilot data or a well-designed trial of arginine in gastroparesis
- Route and formulation feasibility, since current Singapore products are intravenous nutrition formulations and not designed for gastric motility
- A safety plan for patients with renal impairment, acid-base disturbance or heart disease
Other Predicted Indications (for reference)
| Rank | Predicted Indication | Score | Evidence Level | Suggested Action | |------|------|------|------|------| | 2 | Congenital prothrombin deficiency | 98.92% | L5 | Hold; no plausible mechanism, likely a graph artefact | | 3 | Dyspepsia | 97.43% | L4 | Research question; only indirect metabolomic and NO-pathway evidence | | 4 | Vitamin deficiency disorder | 96.92% | L5 | Hold; category too broad, no supporting evidence | | 5 | Sclerosing cholangitis | 96.83% | L5 | Hold; no direct link | | 6 | Obsolete vitamin D deficiency | 96.64% | L5 | Hold; obsolete term, no evidence | | 7 | Biotin metabolic disease | 96.19% | L5 | Hold; no direct link | | 8 | Hypophosphatemic rickets | 95.26% | L5 | Hold; the only arginine-related paper involves a different compound (hexa-D-arginine) | | 9 | Postgastrectomy syndrome | 93.74% | L4 | Hold; only a 1964 historical report | | 10 | Non-syndromic esophageal malformation | 93.41% | L5 | Hold; no evidence, structural defect unlikely to respond |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.